Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Significant Drop in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 56,900 shares, a decrease of 34.9% from the August 15th total of 87,400 shares. Currently, 1.8% of the company’s shares are sold short. Based on an average daily trading volume, of 61,400 shares, the days-to-cover ratio is currently 0.9 days.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets lifted their target price on shares of Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research report on Tuesday, August 20th.

Vivos Therapeutics Stock Up 3.1 %

Shares of NASDAQ:VVOS opened at $2.95 on Monday. The company’s fifty day moving average is $2.54 and its two-hundred day moving average is $2.84. The company has a market cap of $9.52 million, a P/E ratio of -0.27 and a beta of 7.74. Vivos Therapeutics has a 12-month low of $1.91 and a 12-month high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last released its earnings results on Wednesday, August 14th. The company reported ($0.60) earnings per share for the quarter. The business had revenue of $4.05 million for the quarter. Vivos Therapeutics had a negative net margin of 85.90% and a negative return on equity of 652.32%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Vivos Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned approximately 4.29% of Vivos Therapeutics as of its most recent SEC filing. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.